| Bioactivity | SKOG102 is a potent OLIG2 inhibitor that is directly engaging OLIG2 and interferes with the ability of OLIG2 to bind DNA. SKOG102 can be used for the research of glioblastoma (GBM)[1]. |
| Target | OLIG2 |
| Invitro | SKOG102 (0.1-5 μM; 72 h) 抑制人 GBM4 和 GBM8 细胞生长为神经球，IC50 分别为 10.66 和 1.536 μM[1]。SKOG102 (0.5-5 μM; 12 h) 增加 GBM4 细胞中的 p21 RNA 水平并降低 OMG RNA 水平[1]。SKOG102 (5 μM; 20 h) 抑制 OLIG2-DNA 结合，并降低 GBM8 细胞中的丝氨酸磷酸化 OLIG2 和总 OLIG2 蛋白水平[1]。 |
| In Vivo | SKOG102 (10-20 mg/kg; i.p.) 抑制小鼠 GBM4 肿瘤的生长[1]。SKOG102 (5 mg/kg; i.p.) 即使在相对较短的时间内也会在肿瘤中积聚，注射小鼠后 4 小时血浆和脑浓度几乎相同[1]。 Animal Model: |
| Name | SKOG102 |
| CAS | 21062-28-2 |
| Formula | C19H25Cl2N7 |
| Molar Mass | 422.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tsigelny IF, et, al. Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma. Oncotarget. 2017 Apr 4;8(14):22370-22384. |